Results 51 to 60 of about 5,494 (193)

Drug information of Aducanumab and its effectiveness for Alzheimer's disease: A clinical review

, 2021
Alzheimer’s disease (AD) is the main cause of disability in people older than 60 years. More than 1 million cases per year reported in India. AD and other kinds of dementia are more common as individuals become older, affecting 1 in every 14 people over ...
Neel Sureshbhai Raval, null Sachi Anilkumar Chavda, null SP Srinivas Nayak, null Neel Sureshbhai Raval, null Dhwanil Nileshkumar Mithaiwala, null Mohit Buddhdev, null Gunosindhu Chakraborthy   +6 more
core   +1 more source

Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? [PDF]

, 2021
On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (
Jonathan M Schott, Schott, JM, Bart De Strooper, John Hardy, Hardy, J, Lalli, G, De Strooper, B, Giovanna Lalli, De Strooper, Bart, Lalli, Giovanna, Schott, Jonathan M., Hardy, John   +11 more
core   +1 more source

Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer’s disease and cerebral amyloid angiopathy.

Frontiers in Neurology, 2015
Amyloid Related Imaging Abnormalities (ARIA) represent the major severe side effect of amyloid-beta (Aβ) immunotherapy for Alzheimer’s disease (AD).
Jacopo C. DiFrancesco, Jacopo C. DiFrancesco, Martina eLongoni, Martina eLongoni, Fabrizio ePiazza, Fabrizio ePiazza, Fabrizio ePiazza   +6 more
doaj   +1 more source

Therapeutic Ultrasound as a Treatment Modality for Physiological and Pathological Ageing Including Alzheimer’s Disease

Pharmaceutics, 2021
Physiological and pathological ageing (as exemplified by Alzheimer’s disease, AD) are characterized by a progressive decline that also includes cognition. How this decline can be slowed or even reversed is a critical question.
Jürgen Götz, Gina Richter-Stretton, Esteban Cruz   +2 more
doaj   +1 more source

Near‐Infrared Fluorescent PROTAC Enables Theranostic Imaging and Selective Tau Degradation in Alzheimer's Disease

Advanced Science, EarlyView.
Here, we report a novel NIR fluorescent PROTAC platform that enables real‐time imaging and targeted degradation of Alzheimer's p‐Tau. Our lead compound effectively clears p‐Tau, reduces APP/Aβ, and alleviates cognitive deficits in AD mice. This work demonstrates a theranostic strategy for visualizing degradation and developing next‐generation AD ...
Ziwei Ren, Qian Yue, Ning Gao, Qiu‐Lian Hao, Yan Huo, Chuchu Li, Xinyue Leng, Lu‐Lu Sun, Maggie Pui Man Hoi, Hai‐Hao Han, Mingliang Ma, Xu‐Wen Li   +11 more
wiley   +1 more source

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2020
Introduction Amyloid‐related imaging abnormalities (ARIA) are a common, dose‐dependent effect of amyloid‐targeting antibodies, strongly associated with the apolipoprotein E (APOE) ε4 allele.
Lawren VandeVrede, Daniel M Gibbs, Mary Koestler, Renaud La Joie, Peter A. Ljubenkov, Karine Provost, David Soleimani‐Meigooni, Amelia Strom, Elena Tsoy, Gil D. Rabinovici, Adam L. Boxer   +10 more
doaj   +1 more source

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

Frontiers in Neurology, 2022
Second-generation anti-amyloid monoclonal antibodies are emerging as a viable therapeutic option for individuals with prodromal and mild dementia due to Alzheimer's disease (AD).
Charles G. Withington, R. Scott Turner
doaj   +1 more source

Molecular Glue Degraders Enhance CAPRIN1‐Dependent Lysosomal Degradation of APP and Reduce Amyloid β in Alzheimer's Disease

Advanced Science, EarlyView.
A new class of lysosome‐directed molecular glue degraders selectively enhance CAPRIN1–APP interactions, driving APP degradation and reducing amyloid‐β production in human neurons and Alzheimer's disease mouse models. This CAPRIN1‐dependent targeted protein degradation strategy reveals a previously unrecognized therapeutic approach for disrupting the ...
Sunghan Jung, Xu Wang, Bin Liu, Raktim Roy, Nancy Jaiswal, Ratan K. Rai, Yuichiro Takagi, Cen Gao, Lifan Zeng, Ho‐Yin Lo, Reagan K. Wohlford, Ryan K. Higgins, Bruce T. Lamb, Anantha Shekhar, Anita C. Bellail, Chunhai Hao   +15 more
wiley   +1 more source

Cost-effectiveness analysis of aducanumab versus placebo for patients with mild cognitive impairment and mild Alzheimer’s disease

BMJ Open
Objectives To assess the cost-effectiveness of aducanumab at its updated price for treating patients with mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD).Design Cost-effectiveness analysis.Settings A five-state Markov model was ...
Minghui Li, Jing Yuan, Z Kevin Lu, Xiaomo Xiong, Gang Lv, Jacob Jordan King   +5 more
doaj   +1 more source

Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report

Radiology Case Reports, 2023
Patients with Alzheimer's disease who have been given monoclonal antibodies targeting amyloid-β (Aβ) (eg, gantenerumab, donanemab, lecanemab, and aducanumab) for scientific purposes may have a spectrum of imaging findings known as amyloid-related imaging
Houman Sotoudeh, MD, Mohammadreza Alizadeh, MD, Ramin Shahidi, MD, Parnian Shobeiri, MD, MPH, Natelson love, MD, Aparna Singhal, MD   +5 more
doaj   +1 more source